% | $
Quotes you view appear here for quick access.

BASF SE Message Board

  • funfundvierzig funfundvierzig Sep 12, 2013 6:10 AM Flag

    DuPont Management Stooges Falsify Imprelis Insurance Recovery PART II

    Investors, yesterday, Sept. 8, 2013, we caught one resentfully uneducated heckler shilling for DuPont Management and who has specifically targeted us with the abusive and derogatory I.D., "nomofunfun", putting out false and deceptive information on the colossal DuPont
    Imprelis fiasco in a Motley Fool forum. DuPont has not been "almost fully reimbursed by insurers lately", as this dishonest shill alleges. This statement is false and misleading. He knows that.

    Below is the exact disclosure in DuPont's latest quarterly SEC 10-Q filed on July 23, 2013, Note 9 to the Consolidated Financial Statements, in pertinent part:

    "The company has an applicable insurance program with a deductible equal to the first $100 [$million] of costs and expenses. The insurance program limits are $725 [$million] for costs and expenses in excess of the $100 [$million] DuPont has submitted and will continue to submit requests for payment to its insurance carriers for costs associated with this matter. The process of seeking insurance recovery is ongoing and the timing and outcome are uncertain."

    There is no evidence that DuPont has recovered a single dollar of insurance moneys for Imprelis as of June 30, 2013. Furthermore the process of attempting to collect from these unnamed, secret "insurance carriers is "uncertain" and problematic. DuPont's customarily evasive and ultra-secretive Management owes its DD shareholders and investors an explanation as to why there have been no insurance reimbursements to date, more than 2 years after a tsunami of Imprelis claims flooded into Fortress Wilmington and the courts across the nation.

    In the meantime zealous advocates and fans of DuPont Management continue to dissimulate and mislead investors with respect to the enormous magnitude of this costly DuPont Imprelis debacle. Investors should beware and be wary.


87.12+0.36(+0.41%)3:49 PMEDT